

Figure S1. Immunostaining for CTGF in skin samples from PBS or BLM treated WT or *Fli1*$^{+/-}$ mice.

A. The representative pictures of immunostaining for CTGF in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. **B.** The relative number of CTGF-positive fibroblasts and FSP1/CTGF double positive fibroblasts in the dermis. The number per high-power field is adjusted to that in PBS-treated WT mice set at 1 (n = 5). **C.** The representative pictures of immunofluorescence for FSP1 (green) and CTGF (red) in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. Double positive cells were indicated by arrows. Values are the means ± SEM. *P < 0.05. Bars, 10 μm.



Figure S2. Immunostaining for integrin β3 in skin samples from PBS or BLM treated WT or *Fli1*$^{+/-}$ mice

A. The representative pictures of immunostaining for integrin β3 in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. **B.** The relative number of FSP1/integrin β3 double positive fibroblasts in the dermis. The number per high-power field is adjusted to that in PBS-treated WT mice set at 1 (n = 5). **C.** The representative pictures of immunofluorescence for FSP1 (green) and integrin β3 (red) in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. Double positive cells were indicated by arrows. Values are the means ± SEM. *P < 0.05. Bars 10μm



Figure S3. Immunostaining for integrin β5 in skin samples from PBS or BLM treated WT or *Fli1*$^{+/-}$ mice.

A. The representative pictures of immunostaining for integrin β5 in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. **B.** The relative number of FSP1/integrin β5 double positive fibroblasts in the dermis. The number per high-power field is adjusted to that in PBS-treated WT mice set at 1 (n = 5). **C.** The representative pictures of immunofluorescence for FSP1 (green) and integrin β5 (red) in skin samples from WT and *Fli1*+/- mice treated with PBS or BLM. Double positive cells were indicated by arrows. Values are the means ± SEM. *P < 0.05. Bars, 10 μm



Figure S4. The expression profiles of cytokines, chemokines, and M2 macrophage markers in the lesional skin of PBS-treated mice.

mRNA levels of the *Il1b, Il4, Il6, Il10, Il12a, Il17a, Ifng, Tnfa, Mcp1, Arg1, Fizz1,* and *Ym1* genes were measured in the skin of WT and *Fli1*+/- mice with PBS treatment. Values are the means ± SEM (n = 4-8). ND; not determined. AU, arbitrary unit.



Figure S5. The evaluation of inflammatory cell infiltration in mice treated with PBS or BLM.

The representative pictures of F4/80, toluidine blue, CD4, and CD8 staining are shown in the skin of WT and *Fli1*$^{+/-}$ mice at day 7 and 28 after PBS or BLM injection (n = 5).



Figure S6. mRNA levels of the *Col1a2* gene and the levels of soluble type I collagen in the skin of WT and *Fli1*+/- mice.

A. mRNA expression of the *Col1a2* gene in the skin tissue of WT and *Fli1+/-* mice at day 28 after PBS injection were assessed (n = 10). **B.** The levels of soluble type I collagen were elevated in *Fli1*+/- mice. Pepsin-soluble collagen was stained with Coomassie blue (a left panel). Arrows indicate collagen α1(I) and α2(I) subunits. β-components represent cross-linked α-chain dimers. Collagen levels were quantitated using public domain software ImageJ (n = 3; a right panel). Values are the means ± SEM. **P* < 0.05, ****P* < 0.001. AU, arbitrary unit.



Figure S7. mRNA expression of the *ICAM1*, *GlyCAM1, SELP*, and *SELE* genes in the skin tissue of healthy controls and SSc patients.

Skin sections from diffuse cutaneous systemic sclerosis (dcSSc) patients with disease duration of ≤1 year, dcSSc patients with disease duration of >1 year, and healthy controls were assessed (n = 4-6). Values are the means ± SEM. *P < 0.05. AU, arbitrary unit.

Table S1. The sequences of the primers used for qRT-PCR.

Gene	Forward sequence	Reverse sequence
m*Tgfb1*	5' -GCAACATGTGGAACTCTACCAGAA- 3'	5' -GACGTCAAAAGACAGCCACTCA- 3'
m*Ctgf*	5' -GTGCCAGAACGCACACTG- 3'	5' -CCCCGGTTACACTCCAAA- 3'
m*Il1b*	5' -TTGACGGACCCCAAAAGAT- 3'	5' -GAAGCTGGATGCTCTCATCTG- 3'
m*Il4*	5' -CAACGAAGAACACCACAGAG- 3'	5' -GGACTTGGACTCATTCATGG- 3'
m*Il6*	5' -GATGGATGCTACCAAACTGGAT- 3'	5' -CCAGGTAGCTATGGTACTCCAGA- 3'
m*Il10*	5' -TTTGAATTCCCTGGGTGAGAA- 3'	5' -ACAGGGGAGAAATCGATGACA- 3'
m*Il12a*	5' -ACTCTGCGCCAGAAACCTC- 3'	5' -CACCCTGTTGATGGTCACGAC- 3'
m*Il17a*	5' -CTCCAGAAGGCCCTCAGACTAC- 3'	5' -AGCTTTCCCTCCGCATTGACACAG- 3'
m*Ifng*	5' -TCAAGTGGCATAGATGTGGAAGAA- 3'	5' -TGGCTCTGCAGGATTTTCATG- 3'
m*Tnfa*	5' -ACCCTCACACTCAGATCATCTTC- 3'	5' -TGGTGGTTTGCTACGACGT- 3'
m*Mcp-1*	5' -CATCCACGTGTTGGCTCA- 3'	5' -GATCATCTTGCTGGTGAATGAGT- 3'
m*Itgav*	5' -GGTGTGGATCGAGCTGTCTT- 3'	5' -CAAGGCCAGCATTTACAGTG- 3'
m*Itgb3*	5' -GTGGGAGGGCAGTCCTCTA- 3'	5' -CAGGATATCAGGACCCTTGG- 3'
m*Itgb5*	5' -ACCTGCCAAGATGGCATATC- 3'	5' -CACGGACACTTCAAAGGATG- 3'
m*Icam1*	5' -GACGCAGAGGACCTTAACAG- 3'	5' -GACGCCGCTCAGAAGAAC- 3'
m*Glycam-1*	5' -GACGCAGAGGACCTTAACAG- 3'	5' -GACGCCGCTCAGAAGAAC- 3'
m*Selp*	5' -TCCAGGAAGCTCTGACGTACTTG- 3'	5' -GCAGCGTTAGTGAAGACTCCGTAT- 3'
m*Sele*	5' -TGAACTGAAGGGATCAAGAAGACT- 3'	5' -GCCGAGGGACATCATCACAT- 3'
m*Arg1*	5' -CAGAAGAATGGAAGAGTCAG - 3'	5' -CAGATATGCAGGGAGTCACC- 3'
m*Fizz1*	5' -TCCCAGTGAATACTGATGAGA- 3'	5' -CCACTCTGGATCTCCCAAGA- 3'
m*Ym1*	5' -GGGCATACCTTTATCCTGAG- 3'	5' -CCACTGAAGTCATCCATGTC- 3'
m*Gapdh*	5' -CGTGTTCCTACCCCCAATGT- 3'	5' -TGTCATCATACTTGGCAGGTTTCT- 3'
h*ITGAV*	5' -GCCGTGGATTTCTTCGTG- 3'	5' -GAGGACCTGCCCTCCTTC- 3'
h*ITGB3*	5' -CGCTAAATTTGAGGAAGAACG- 3'	5' -GAAGGTAGACGTGGCCTCTTT- 3'
h*ITGB5*	5' -GGAGTTTGCAAAGTTTCAGAGC- 3'	5' -TGTGCGTGGAGATAGGCTTT- 3'
h*CTGF*	5' -TTGCGAAGCTGACCTGGAAGAGAA- 3'	5' -AGCTCGGTATGTCTTCATGCTGGT - 3'
h*ICAM1*	5' -TAGAGACCCCGTTGCCTAAA- 3'	5' -TCATACACCTTCCGGTTGTTC- 3'
h*GlyCAM-1*	5' -TGAAATTCACTCGGAGACTGC- 3'	5' -TGGCAAGTTTTCCCTCTGA- 3'
h*SELP*	5' -TTAGTTGGACCGGAAGTGGT- 3'	5' -CAGGTGCTGACACTGCACA- 3'
h*SELE*	5' -ACCAGCCCAGGTTGAATG- 3'	5' -GGTTGGACAAGGCTGTGC- 3'
h*VE-cadherin*	5’ -AAGCCTCTGATTGGCACAGT- 3’	5’ –CTGGCCCTTGTCACTGGT- 3’
h*ACTA2*	5' -CCGACCGAATGCAGAAGGA- 3'	5' -ACAGAGTATTTGCGCTCCGAA- 3'
h*FSP1*	5' -GTCCACCTTCCACAAGTAC- 3'	5' -TGTCCAAGTTGCTCATCAG- 3'
h*SNAI1*	5' -ACCCCAATCGGAAGCCTAACT- 3'	5' -GGTCGTAGGGCTGCTGGAA- 3'
h*FLI1*	5’-GGATGGCAAGGAACTGTGTAA-3'	5’-GGTTGTATAGGCCAGCAG-3’
h*GAPDH*	5’ -ACCCACTCCTCCACCTTTGA- 3’	5’ -CATACCAGGAAATGAGCTTGACAA- 3’

Table S2. Primers for ChIP.

Gene	Forward sequence	Reverse sequence
h*SELE*	5' -ATTTCCAAGGGCCATTTACC- 3'	5' -TTCCTTACCCTCCTCCTCCT- 3'
h*SELP*	5' -TCTCCAGTGGTTGCTGTTGA- 3'	5' -TTGAGGGACAGTGACTGGTG- 3'
h*ICAM1*	5' -CGGTGTAGACCGTGATTCAA- 3'	5' -GCTGCAGTTATTTCCGGACT- 3'
h*FSP1*	5' -CCCCTAGCTTTTGTGTCACC- 3'	5' -GGTAACGGGTAAGCCCTAGC- 3'
h*SNAI1*	5’ -AGAAGCTACCCTTCGGGAGA- 3’	5’ -GCATTGACGAGGGAAACG- 3’